Please join us for a candid discussion between Genzyme CEO, David Meeker, and Boston Globe healthcare and life sciences reporter, Robert Weisman, on the value, economics, and perception of drugs and drug development. The annual healthcare cost in the United States is roughly $4 trillion per year and rising. This large and ever increasing cost drives a national debate on ways to control and reduce healthcare spending. The perceived high cost of drugs has become a preferred target, despite only accounting for 10% of the total healthcare costs. Some argue that drugs are overpriced while others believe that novel drugs are the key to reducing healthcare costs.
Send this to a friend